Literature DB >> 21271308

Advances in primary CNS lymphoma: randomized clinical trials of chemotherapy and whole-brain radiotherapy.

Lauren E Abrey1.   

Abstract

Entities:  

Year:  2011        PMID： 21271308     DOI： 10.1007/s11910-011-0183-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  10 in total

1.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

2.  High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.

Authors:  K Jahnke; A Korfel; P Martus; M Weller; U Herrlinger; A Schmittel; L Fischer; E Thiel
Journal:  Ann Oncol       Date:  2005-01-14       Impact factor: 32.976

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

Authors:  Kristoph Jahnke; Eckhard Thiel; Peter Martus; Ulrich Herrlinger; Michael Weller; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

5.  A multicenter study of treatment of primary CNS lymphoma.

Authors:  A J M Ferreri; M Reni; F Pasini; A Calderoni; U Tirelli; A Pivnik; G M Aondio; F Ferrarese; H Gomez; M Ponzoni; B Borisch; F Berger; C Chassagne; P Iuzzolino; A Carbone; J Weis; E Pedrinis; T Motta; A Jouvet; T Barbui; F Cavalli; J Y Blay
Journal:  Neurology       Date:  2002-05-28       Impact factor: 9.910

Review 6.  Therapeutic challenges in primary CNS lymphoma.

Authors:  Patrick G Morris; Lauren E Abrey
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

7.  Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.

Authors:  L Fischer; P Martus; M Weller; H A Klasen; B Rohden; A Röth; B Storek; M Hummel; T Nägele; E Thiel; A Korfel
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

8.  The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas.

Authors:  Lars Fischer; Kristoph Jahnke; Peter Martus; Michael Weller; Eckhard Thiel; Agnieszka Korfel
Journal:  Haematologica       Date:  2006-03       Impact factor: 9.941

9.  Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Authors:  M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

10.  Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study.

Authors:  Hendrik Pels; Annika Juergens; Axel Glasmacher; Holger Schulz; Andreas Engert; Michael Linnebank; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Monika Lamprecht; Peter Hau; Martina Deckert; Rolf Fimmers; Christopher Bangard; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  J Neurooncol       Date:  2008-10-18       Impact factor: 4.130
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.